蛋白磷酸酶在病理性心肌肥厚中的研究进展  

Protein phosphatases in pathological cardiac hypertrophy

作　　者：张旭涛 夏豪[1,2,3] ZHANG Xutao;XIA Hao(Department of Cardiology,Renmin Hospital of Wuhan University,Wuhan 430060,China;Cardiovascular Research Institute,Wuhan University,Wuhan 430060,China;Hubei Key Laboratory of Cardiology,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院心内科,武汉430060 [2]武汉大学心血管病研究所,武汉430060 [3]心血管病湖北省重点实验室,武汉430060

出　　处：《医学新知》2024年第4期458-465,共8页New Medicine

基　　金：国家自然科学基金青年科学基金项目(81900364)。

摘　　要：病理性心肌肥厚是持续机械、化学刺激导致的多种心血管疾病共有的病理改变,最终会导致心力衰竭、心律失常等。目前的临床防治手段尚不理想,因此,明确病理性心肌肥厚的调控机制,开发有效的治疗靶点,对延缓病理性心肌肥厚进展具有重要意义。近年来,越来越多的证据表明蛋白磷酸酶在病理性心肌肥厚的发生发展中发挥重要作用。大量动物实验显示,对蛋白磷酸酶或蛋白磷酸酶的底物进行直接调控足以有效改善小鼠病理性心肌肥厚。本文对蛋白磷酸酶参与的病理性心肌肥厚过程进行概述,探讨调控蛋白磷酸酶及其底物在病理性心肌肥厚临床防治中的潜在价值。Pathological cardiac hypertrophy is a pathological change of various cardiovascular disease,caused by persistent mechanical and chemical stimulation,which ultimately leads to heart failure and arrhythmia.The clinical therapeutic means of prevention cannot be satisfied by the prevention and treatment strategies currently.Therefore,it is crucial to clarify the regulatory mechanisms of pathological cardiac hypertrophy and developing effective therapeutic targets in slowing down the growth of pathological cardiac hypertrophy.In recent years,there has been increasing evidence that protein phosphatases play an important role in mediating dephosphorylation in pathological cardiac hypertrophy.Numerous animal studies have demonstrated that pathological cardiac hypertrophy of mice can be efficiently treated by directly regulating protein phosphatases or protein phosphatase substrates.This review elaborated the role that protein phosphatases play in the pathological cardiac hypertrophy process and highlighted the potential advantages of regulating protein phosphatases and its substrates in the clinical prevention and treatment of pathological cardiac hypertrophy.

关 键 词：病理性心肌肥厚 蛋白磷酸酶 去磷酸化 组蛋白去乙酰化酶 活化T细胞核因子 

分 类 号：R542.2[医药卫生—心血管疾病]